In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.
0:04- Intro
0:34- Fruquintinib and its mechanism of action
1:34- About the FRESCO trial
3:11- FRESCO-2 background
4:22- Findings from the FRESCO-2 study
4:54- What does this approval mean in mCRC?
6:15- Managing toxicities
7:54- Main takeaways
9:04- Looking forward
In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, associate professor in the Department of Gastrointestinal Medical Oncology in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer (mCRC).
On November 8, 2023, the FDA granted approval to fruquintinib (HMPL-013) for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.1
Dasari explains that fruquintinib is a selective inhibitor of VEGFR-1, -2, and -3. Previously, the agent has inhibited the migration, proliferation, and survival of endothelial cells and also inhibited microvessel formation, tumor cell proliferation, and tumor cell death.
According to Dasari, data from the FRESCO-2 study (NCT04322539) support this regulatory decision. In the phase 3 study, fruquintinib led to a reduction in the risk of death by 34% when given to patients with refractory mCRC. The median overall survival (OS) seen with fruquintinib was 7.4 months compared with 4.8 months with best supportive care in the study. These data represent a significant improvement in OS (HR, 0.66; 95% CI, 0.55-0.80; P < .0001).2,3
In terms of safety, Dasari highlights some of the adverse events observed in the study, including fatigue, hand-foot syndrome, and issues with liver function tests, but notes that they were rare, reflecting the good toxicity profile of the agent.
With this new approval, Dasari looks forward to the future development of fruquintinib beyond its current indication. He hopes to see the agent move into earlier lines of therapy and given in combination with other drugs to build upon its efficacy.
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Phase 3 Trials of Botensilimab/Balstilimab Move Forward, Despite FDA's Approval Setback
July 18th 2024Agenus was advised by the FDA against filing for accelerated approval of botensilimab plus balstilimab for relapsed/refractory microsatellite stable metastatic colorectal cancer without liver metastases.
Read More
Further Evaluation of Regorafenib/Nivolumab Is Recommended in Rectal Cancer
July 2nd 2024An interim analysis of the phase 2 REGINA trial met predefined statistical criteria and suggests the need for further evaluation of the combination of regorafenib, nivolumab, and short-course radiation therapy in patients with locally advanced rectal cancer.
Read More
